Medical Treatment of Hirsutism in Women
- PMID: 20491644
- DOI: 10.2174/092986710791556005
Medical Treatment of Hirsutism in Women
Abstract
Hirsutism is the presence of excess hair growth in women in the typical male hair growth areas, thereby reflecting a deviation from the normal female hair pattern. It affects from 5% to 10% of women, depending on age, menopausal status and ethnic background. The presence of hirsutism is very distressing for women, and subsequently may have a negative impact on their psychosocial life. In the treatment of hirsutism several options are now available, including pharmacologic regimens and cosmetic measures. Both the hormonal profile of the patient and her expectations and preferences should guide the therapeutic approach. The aims of the medical therapy are suppression of excessive androgen production, inhibition of peripheral action of androgens, and treatment of patients at risk for metabolic disorders or reproductive cancers. For other diseases related to endocrine abnormalities, such as thyroid disorders or Cushing's syndrome, specific treatment is mandatory. After an ineffective local approach by direct hair removal, a pharmacological treatment should be suggested, using estrogen and progestin combinations, antiandrogens (i.e. cyproterone acetate, spironolactone) or both as a first line. Finasteride, gonadotropin-releasing hormone agonists, and glucocorticoids should be used in selected cases. Adequate contraception is also recommended if antiandrogens are used. Unfortunately, since systemic therapy reduces hair growth in less than 50% of cases, hirsute women frequently require cosmetic measures. The use of a logical combination of different options has been shown to achieve a satisfactory result in most cases. This review provides information and suggestions about the current options of treating hirsutism.
Similar articles
-
The evaluation and management of hirsutism.Obstet Gynecol. 2003 May;101(5 Pt 1):995-1007. doi: 10.1016/s0029-7844(02)02725-4. Obstet Gynecol. 2003. PMID: 12738163 Review.
-
Hirsutes. II: Treatment.Australas J Dermatol. 1998 Aug;39(3):151-7. doi: 10.1111/j.1440-0960.1998.tb01271.x. Australas J Dermatol. 1998. PMID: 9737040 Review.
-
Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism.J Clin Endocrinol Metab. 1991 May;72(5):1008-13. doi: 10.1210/jcem-72-5-1008. J Clin Endocrinol Metab. 1991. PMID: 1827125 Clinical Trial.
-
Anti-androgen treatments.Ann Endocrinol (Paris). 2010 Feb;71(1):19-24. doi: 10.1016/j.ando.2009.12.001. Epub 2010 Jan 22. Ann Endocrinol (Paris). 2010. PMID: 20096826 Review.
-
[Hirsutism].Ned Tijdschr Geneeskd. 2007 Oct 20;151(42):2313-8. Ned Tijdschr Geneeskd. 2007. PMID: 18064932 Review. Dutch.
Cited by
-
Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome.Endocrine. 2012 Dec;42(3):526-34. doi: 10.1007/s12020-012-9701-4. Epub 2012 Jun 4. Endocrine. 2012. PMID: 22661293 Free PMC article. Review.
-
Interventions for hirsutism (excluding laser and photoepilation therapy alone).Cochrane Database Syst Rev. 2015 Apr 28;2015(4):CD010334. doi: 10.1002/14651858.CD010334.pub2. Cochrane Database Syst Rev. 2015. PMID: 25918921 Free PMC article.
-
A Narrative Review of Herbal Remedies for Managing Hirsutism.Int J Prev Med. 2024 Mar 28;15:17. doi: 10.4103/ijpvm.ijpvm_62_23. eCollection 2024. Int J Prev Med. 2024. PMID: 38715699 Free PMC article. Review.
-
Hyperprolactinemia and Hirsutism in Patients Without Polycystic Ovary Syndrome.Int J Trichology. 2016 Jul-Sep;8(3):130-4. doi: 10.4103/0974-7753.188998. Int J Trichology. 2016. PMID: 27625565 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources